Home > News > featured news > Medicago Announces Publication of Phase 3 COVID-19 Vaccine Study Results in New England Journal of Medicine

Future of Healthcare

Medicago Announces Publication of Phase 3 COVID-19 Vaccine Study Results in New England Journal of Medicine

Medicago | May 06, 2022

Medicago announced the publication of the results from the Phase 3 study of COVIFENZ®, COVID-19 vaccine recombinant, adjuvanted, in the New England Journal of Medicine. The Phase 3 trial studied the two-dose regimen of COVIFENZ® given 21 days apart versus placebo in over 24,000 subjects aged 18 and above. Common side effects in the vaccine group included injection site pain, headache, fatigue, fever, muscle aches, and chills.

COVIFENZ® is indicated for active immunization to prevent coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 in individuals 18 to 64 years of age. The safety and efficacy of COVIFENZ® in individuals younger than 18 years of age or 65 years and older have not been established. COVIFENZ® has not yet received approval in other jurisdictions.

“We are proud to have our Phase 3 clinical trial published in the esteemed New England Journal of Medicine to be shared with the larger scientific community. Medicago’s scientific team has dedicated decades to the development of our proprietary plant-based vaccine manufacturing platform, and we are thrilled to see our results disseminated in this way. We hope that this exchange of research and knowledge will encourage and inspire future innovation in biomedical science and clinical practice.”

Marc-André D’Aoust, Executive Vice President, Innovation, Development and Medical Affairs at Medicago

COVIFENZ® was authorized for use by Health Canada on February 24, 2022. This is the first authorized COVID-19 vaccine developed by a Canadian-headquartered company, and the first that uses a plant-based protein technology.

“The world needs a diverse range of vaccine options to continue to fight COVID-19, and we are proud to be able to contribute,” said Toshifumi Tada, CEO and President at Medicago.

About Medicago

Medicago is on a mission to help improve global public health using the power of plants. Founded in 1999 with the belief that innovative approaches and rigorous research would bring new solutions in healthcare, Medicago is a pioneer in plant-based therapeutics. We are proudly rooted in Quebec, with manufacturing capacity in both Canada and the US. Our passionate and curious team of over 500 scientific experts and employees are dedicated to using our technology to provide rapid responses to emerging global health challenges, and to advancing therapeutics against life-threatening diseases worldwide. Medicago is an affiliated company of Mitsubishi Tanabe Pharma Corporation.

About Mitsubishi Tanabe Pharma Corporation

Mitsubishi Tanabe Pharma Corporation, the majority parent company of Medicago, is one of the large Japanese pharmaceutical companies, with its headquarters in Osaka, Japan. It positions vaccines as one of its key R&D areas and is also working to develop new modalities of vaccines. MTPC will further contribute to the prevention of infectious diseases which is one of the world’s important social issues, by delivering a new option of plant-based VLP vaccine as a new type of vaccine. MTPC is a member of Mitsubishi Chemical Holdings Group.

Spotlight

Accelerate Breakthroughs in Health Care and Life Sciences with SAS

The answers to the world’s toughest health care challenges are in the data. SAS helps customers bring together a complex ecosystem of health care and life sciences data, accelerate insights and improve lives. Let’s find your next breakthrough.

More featured news

Spotlight

Accelerate Breakthroughs in Health Care and Life Sciences with SAS

Related News

Digital Healthcare, Healthcare Analytics

Xenex Announces World’s First Disinfection Tracking System

Businesswire | June 27, 2023

Portable Medical Equipment (PME) such as IV pumps, workstations on wheels (WOWs), and vitals machines can carry and transfer dangerous pathogens between rooms and patients within healthcare facilities because the equipment is often used and rolled between multiple patient rooms. Recognizing the importance of being able to track and report disinfection, Xenex Disinfection Services today announced TrackMate™, a patented device developed by hospitals for hospitals that provides automated tracking of disinfection/cleaning events for PME and hospital rooms. It’s the world’s first automated tracking system and solution for The Joint Commission standard IC 02.02.01 EP1, which focuses on the disinfection of PME. TrackMate is a small, easy-to-use device that attaches to PME and registers each disinfection\cleaning event stores the data in a secure portal, and provides the data that can be used for compliance and The Joint Commission reporting. Peer-reviewed studies demonstrated that twice as many PME disinfection events occurred when TrackMate was deployed and 100% of disinfection events were tracked and reported for compliance. TrackMate replaces low tech and often labor-intensive monitoring solutions currently being used in healthcare facilities, such as equipment tags, clipboards and paper checklists, and plastic bags placed over IV poles. It eliminates the need for the manual collection of disinfection event data for Joint Commission compliance reporting. In addition to tracking disinfection events for PME and rooms, TrackMate can be used anywhere there is a need for tracking disinfection/cleaning, logging of cleaning activity, or automated and remote monitoring of cleaning activity. For example, tracking the cleaning of surfaces in patient rooms, emergency and waiting rooms, nurse stations, kitchens, microbiology laboratories and mannequins in simulation centers. “Healthcare workers can’t look at an IV pole and know when it was last disinfected, which is why TrackMate is such a game changer. For the first time, disinfection/cleaning event status is being delivered to the user at the point of care. Nurses can quickly look at TrackMate and see when the last disinfection/cleaning event occurred. The CDC has stated that Candida auris is commonly spread via PME – so it’s incredibly important to know when the PME was last cleaned. Infection preventionists and hospital compliance personnel are going to be very excited to learn that we have a solution to IC 02.02.01,” said Dr. Mark “Tuck” Stibich, co-founder and Chief Scientific Officer of Xenex. TrackMate was invented by Dr. Chetan Jinadatha, Chief of the Infectious Diseases Division at the Central Texas Veterans Health Care System and Clinical Professor, School of Medicine, Texas A&M University. Commercialization of TrackMate is supported by the VA Technology Transfer Program, which facilitates the commercialization of VA inventions to benefit Veterans and the American public. Funding from the National Institutes of Health (NIH) and Central Texas Veterans Healthcare System supported scientific evaluation of the technology. TrackMate is a small (2”x5”) device that attaches to PME or can be placed in a room. It senses moisture (wipes) or UV light irradiation, collects all of the disinfection/cleaning events and keeps a log locally and online. Events are transmitted once a day through cellular signal to an online database. Supervisors can log in and retrieve the cleaning log for improving cleaning practices or validate compliance with policy. Battery life on each device is 3 years. About Xenex Disinfection Services Xenex is a world leader in innovative UV technology-based disinfection strategies and solutions. Xenex's mission is to enable its partners to save lives and reduce suffering by destroying the deadly microorganisms that can cause infections. Xenex is backed by well-known investors that include EW Healthcare Partners, Piper Sandler, Malin Corporation, Battery Ventures, Targeted Technology Fund II, Tectonic Ventures and RK Ventures.

Healthtech Security

Quantum Health Partners With Progyny To Launch New Family-Building Benefits Offering

Businesswire | July 06, 2023

Quantum Health, the leading consumer healthcare navigation and care coordination company, announced today it has partnered with Progyny, Inc. (Nasdaq: PGNY) as part of its launch of a new family-building benefits offering to help employers provide a better, more comprehensive and inclusive experience for all employees who need support to build their families. Progyny, a leading benefits management company specializing in fertility and family-building benefits solutions, will be included as a new Preferred Partner within Quantum Health’s Comprehensive Care Solutions™ platform. As part of this new offering, Quantum Health will fully integrate Progyny’s solution, including access to its national and actively managed network of top fertility specialists, dedicated concierge patient support, integrated pharmacy and wraparound technology, into Quantum Health’s navigation and engagement platform. Quantum Health’s 500 employer clients, currently supporting close to 3 million members, can now elect Progyny’s comprehensive fertility and family-building benefits with an accelerated contracting and implementation process and seamless integration. “Quantum Health has long supported our clients and members with their reproductive health needs, but there is growing demand for a more comprehensive and integrated family-building experience, especially for groups of people who may face heightened barriers to accessing fertility care,” said Quantum Health President Shannon Skaggs. “After evaluating the market, we are excited to partner with Progyny, one of the market’s leading solutions in delivering an exceptional family-building experience that leads to healthy pregnancies. We already share mutual clients with Progyny and are eager to integrate their offering into our navigation engagement platform to better meet the needs of our clients and their millions of employees across the country.” The recent Mercer survey, Health & Benefit Strategies for 2024, found over 40% of employers currently take steps to provide equitable family-building benefits, including fertility treatments that do not require individuals to meet the clinical definition of infertile, and coverage for surrogacy expenses. Yet, in the recent Employee Benefit News and Quantum Health State of Healthcare national study, 43% of employers and 28% of employees reported that their company does not currently offer family-building assistance, including fertility and/or adoption assistance. Additionally, 30% to 35% of those in younger workforce generations (e.g., Gen Z, millennials and Gen X) say they want family-building assistance benefits but don’t currently have them, an important consideration for employers as they support their future workforce. “At Progyny, we share Quantum Health’s goal of delivering superior outcomes, exceptional member support and sustained cost savings. Through this partnership, Quantum Health’s leading employer clients can easily expand their benefits offering to include the comprehensive, equitable and inclusive family-building services their workforce increasingly seeks,” said Dr. Janet Choi, Chief Medical Officer of Progyny. “We are excited to integrate our solution into Quantum Health’s unique navigation and member engagement platform to further expand access to our fertility and family-building services and to help members engage with the specialists and treatment they need more quickly and comprehensively.” Quantum Health has recognized the increasing demand by employers and their employees for more holistic family-building solutions. By integrating Progyny’s unique benefits design and highly curated network of specialists with Quantum Health’s proprietary care management and Real-Time Intercept® model, members on family-building journeys will now be guided to all the support they need by their trusted Healthcare Warriors®. Through human-centered engagement, Quantum Health serves as the single point of contact for healthcare benefits questions, such as family-building support, and will direct members to the right resource at the right time, resulting in better experiences, reduced stress for the members and better outcomes. This new partnership with Progyny provides employers with a comprehensive family-building solution that complements Quantum Health’s integrated services, including the Early Steps® Maternity program, a high-risk pregnancy program that pairs expectant parents with a Personal Care Guide nurse for guidance. In the coming months, Quantum Health will continue expanding its Preferred Partners™ program for building families, along with addressing other high-demand and top cost-driving categories for employers. About Quantum Health Quantum Health is the industry-leading consumer healthcare navigation and care coordination company that delivers an unparalleled consumer experience to its members, as well as validated claims savings and high satisfaction rates for its self-insured employer clients. Quantum Health’s proprietary Real-Time Intercept® model identifies opportunities for early intervention in a member’s healthcare journey, resulting in better engagement, outcomes and cost efficiencies. The company was founded in 1999 and is based in Dublin, Ohio. Since its inception, Quantum Health has earned numerous awards and honors, including being named among the Fastest-Growing Private Companies by Inc. 5000, and a Great Place to Work by FORTUNE Magazine and Entrepreneur Magazine. Quantum Health has consistently been named one of the 50 Fastest-Growing Women-Owned/Led Companies by the Women Presidents Organization, and Columbus Business First has consecutively honored Quantum Health as a Best Place to Work.

Digital Healthcare, Medical Devices

Massive Bio and Datavant Expand Partnership to Integrate Datavant’s Medical Record Retrieval Capabilities to Revolutionize Patient Care

Globenewswire | July 03, 2023

Massive Bio, a leader in leveraging artificial intelligence and concierge services to empower cancer patients, and Datavant, the leader in helping organizations securely connect data, are thrilled to announce an expanded partnership that leverages Datavant’s national scale in medical record retrieval and Massive Bio’s expertise in AI-driven clinical trial matching to accelerate clinical research and improve patient care in cancer. This expanded partnership builds upon an earlier pilot that enabled Massive Bio to request, retrieve, and digitally deliver clinical data with higher reliability, faster speed and greater coverage across sites of care, thus significantly improving patient outcomes while ensuring compliance and data privacy. Massive Bio's CEO, Selin Kurnaz, emphasizing the significance of this partnership states, "By integrating Datavant's cutting-edge technology, we are making a leap in the provision of personalized cancer treatments. This collaboration empowers us to access patient medical records for any patient in the country in a scalable, secure and compliant manner, thereby accelerating our ability to provide data-driven, personalized care." Dr. Arturo Loaiza-Bonilla, Co-Founder and Chief Medical Officer at Massive Bio, adds, "By leveraging the Datavant Switchboard, we are strategically positioned to drive meaningful cost savings while improving patient care. Especially for our oncology patients, the ability to obtain complete clinical histories from the medical record would be a challenge. We are thrilled to be working with Datavant, whose national scale of data connectivity can help us access full medical records, including unstructured data, that is essential to our work. Datavant is transforming how clinical data is used and shared, ultimately bringing us closer to achieving our mission of providing the right treatment to the right patient at the right time." "We are excited about this partnership with Massive Bio. Their innovative approach to personalized cancer care aligns with our mission of securely connecting health data to improve patient outcomes," says Tal Rosenberg, President, Emerging Businesses & Chief Partnerships Officer at Datavant. "This collaboration not only marks a significant step forward in patient care but also emphasizes our shared commitment to reducing friction and increasing security in health data exchange." With this expanded partnership, Massive Bio will integrate Datavant’s medical record retrieval capabilities into Massive Bio’s operations in order to expedite the identification of potential clinical trial participants and speed up time to insight in clinical research. About Datavant Datavant's mission is to connect the world's health data to improve patient outcomes. Datavant works to reduce the friction of data sharing across the healthcare industry by building technology that protects the privacy of patients while supporting the linkage of patient health records across datasets. About Massive Bio Massive Bio is at the forefront of empowering cancer patients to discover their optimal treatment options. Utilizing AI to enhance equitable access and precision targeting for clinical trial matching, drug matching, and drug development, Massive Bio is committed to breaking down barriers in clinical trial enrollment, fostering value-based oncology decisions, and facilitating data-driven cancer treatment. Serving over three dozen pharmaceutical companies, contract research organizations, and hospital networks, Massive Bio has earned recognition from the National Cancer Institute with an SBIR contract. Founded in 2015 by a team of clinical, technology, and M&A executives, Massive Bio boasts a global presence with nearly 100 people across 12 countries.